Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.61 |
| ▸ | HPGD | P15428 | 6/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 6/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24663122 | 0.87 | ALDH1A1 (0.54) | ALDH1A1HPGDMAPTMEN1KMT2A | |
| SCHEMBL12876531 | 0.86 | ALDH1A1 (0.48) | ALDH1A1HPGDMAPTMEN1KMT2A | |
| SCHEMBL3914366 | 0.84 | NPC1 (0.70) | ALDH1A1HPGDMAPTMEN1KMT2A | |
| SCHEMBL3100114 | 0.84 | TSHR (0.54) | ALDH1A1HPGDMAPTMEN1KMT2A | |
| SCHEMBL28745641 | 0.84 | ALDH1A1 (0.52) | ALDH1A1HPGDMAPTMEN1KMT2A | |
| SCHEMBL3102333 | 0.84 | ALDH1A1 (0.62) | ALDH1A1HPGDMAPTMEN1KMT2A | |
| SCHEMBL3091048 | 0.84 | SLC6A4 (0.51) | ALDH1A1HPGDMAPTMEN1KMT2A | |
| SCHEMBL1597664 | 0.84 | RAB9A (0.50) | ALDH1A1HPGDMAPTMEN1KMT2A | |
| SCHEMBL3111952 | 0.84 | NR4A1 (0.50) | ALDH1A1HPGDMAPTMEN1KMT2A | |
| SCHEMBL3101891 | 0.84 | ALDH1A1 (0.57) | ALDH1A1HPGDMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394835-B2 | Aromatic compounds and their use in medical applications | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2013-03-12 | — | — | US | disclosed |
| US-8367677-B2 | Comprising trihydroxy phenyl subunits; selectin inhibitors; side effect reduction; 3-{3-[3-(3,4,5-Trihydroxy-phenyl)-propionylamino]-phenylamino}-benzoic acid | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2013-02-05 | — | — | US | disclosed |
| US-8367677-B2 | Comprising trihydroxy phenyl subunits; selectin inhibitors; side effect reduction; 3-{3-[3-(3,4,5-Trihydroxy-phenyl)-propionylamino]-phenylamino}-benzoic acid | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2013-02-05 | — | — | US | disclosed |
| EP-1940372-B1 | NOVEL AROMATIC COMPOUNDS AND THEIR USE IN MEDICAL APPLICATIONS | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2011-11-09 | — | — | EP | disclosed |
| US-20110152291-A1 | NOVEL AROMATIC COMPOUNDS AND THEIR USE IN MEDICAL APPLICATIONS | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2011-06-23 | — | — | US | disclosed |
| US-7923473-B2 | Moderate binding of selectins ; chronic obstructive pulmonary disease; Crohn's disease; sepsis; antiinflammatory agents; skin disorders; antiarthritic agents; cardiovascular disorders; autoimmune diseases ' | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2011-04-12 | — | — | US | disclosed |
| US-7923473-B2 | Moderate binding of selectins ; chronic obstructive pulmonary disease; Crohn's disease; sepsis; antiinflammatory agents; skin disorders; antiarthritic agents; cardiovascular disorders; autoimmune diseases ' | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2011-04-12 | — | — | US | disclosed |
| US-20110054017-A1 | SUBSTITUTED FURANS AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2011-03-03 | — | — | US | disclosed |
| US-20110054017-A1 | SUBSTITUTED FURANS AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2011-03-03 | — | — | US | disclosed |
| US-20110054017-A1 | SUBSTITUTED FURANS AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2011-03-03 | — | — | US | disclosed |
| WO-2009097991-A1 | SUBSTITUTED FURANS AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-08-13 | — | — | WO | disclosed |
| US-20080249107-A1 | Non-Glycosylated/Non-Glycosidic/Non-Peptidic Small Molecule Psgl-1 Mimetics for the Treatment of Inflammatory Disorders | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2008-10-09 | — | — | US | disclosed |
| US-20080249107-A1 | Non-Glycosylated/Non-Glycosidic/Non-Peptidic Small Molecule Psgl-1 Mimetics for the Treatment of Inflammatory Disorders | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2008-10-09 | — | — | US | disclosed |
| US-20080207639-A1 | Novel Aromatic Compounds and Their Use in Medical Applications | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2008-08-28 | — | — | US | disclosed |
| US-20080207639-A1 | Novel Aromatic Compounds and Their Use in Medical Applications | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2008-08-28 | — | — | US | disclosed |
| WO-2007039113-A1 | NOVEL AROMATIC COMPOUNDS AND THEIR USE IN MEDICAL APPLICATIONS | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2007-04-12 | — | — | WO | disclosed |
| EP-1764093-A1 | Novel aromatic compounds and their use in medical applications | Revotar Biopharmaceuticals AG (DE) | 2007-03-21 | — | — | EP | disclosed |
| WO-2002000612-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152291-A1 | NOVEL AROMATIC COMPOUNDS AND THEIR USE IN MEDICAL APPLICATIONS | SELP, SELL, SELE | ALDH1A1 328/4885HPGD 1382/4885MAPT 2028/4885 |
| US-20080207639-A1 | Novel Aromatic Compounds and Their Use in Medical Applications | SELP, SELL, SELE | ALDH1A1 239/4885HPGD 1376/4885MAPT 1963/4885 |
| US-20110054017-A1 | SUBSTITUTED FURANS AND THEIR USE | XDH, TXN2, FABP3 | ALDH1A1 424/4885HPGD 134/4885MAPT 4648/4885 |
| US-20080249107-A1 | Non-Glycosylated/Non-Glycosidic/Non-Peptidic Small Molecule Psgl-1 Mimetics for the Treatment of Inflammatory Disorders | SELP, SELPLG, SELE | ALDH1A1 2010/4885HPGD 2227/4885MAPT 4335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.